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Abstract
Doxorubicin (DOX) is a powerful chemotherapy that functions by interfering with cancer
cells’ growth. However, the use of DOX is limited due to its detrimental side effects that can
lead to serious cardiovascular complications. Our goal is to determine if nicotinamide
mononucleotide (NMN) and histone acetyltransferase (HAT) inhibitors can protect against
DOX-induced cardiotoxicity. Our findings revealed that DOX reduced NAD+ concentration
and induced damage to H9c2 cells as evidenced by higher caspase-3 activity and lactate
dehydrogenase release. Pre-incubation with NMN increased NAD+ concentration and
attenuated DOX-induced damage. There was higher cell viability in the NMN pre-incubated
group compared to the vehicle treated group in response to DOX. Furthermore, mice pretreated with NMN had higher ejection fraction and fraction shortening percentage compared
to the vehicle treated group. In contrast, pre-incubation with HAT inhibitors failed to protect
DOX-treated cells. Thus, our study suggests that NMN may be a potential drug that prevents
DOX-induced cardiotoxicity.

Keywords
cardiotoxicity, cell death, Doxorubicin, histone acetyltransferase, nicotinamide adenine
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Summary for Lay Audience
With about 9.8 million patients worldwide needing treatment annually, chemotherapy is a
widely used treatment option for cancer patients. Doxorubicin (DOX) is a well-established
chemotherapy drug that is prescribed for a diverse range of cancer types. DOX has a
drawback as it causes heart damage, which is referred to as DOX-induced cardiotoxicity. In
severe cases, DOX-induced cardiotoxicity can result in heart failure leading to death, even
years after the patient has stopped their treatment.

The imbalance between histone deacetylase and histone acetyltransferase activity may be the
main cause of DOX-induced cardiotoxicity. Histone deacetylases are enzymes that function
to removes chemical molecules called acetyl groups. Previous research in our laboratory
showed that nicotinamide riboside, a compound similar to Vitamin B3, protected against
DOX-induced cardiotoxicity. We found that when cells take in nicotinamide riboside, it is
converted into a molecule called nicotinamide adenine dinucleotide (NAD+). NAD+ will
activate a group of histone deacetylase called Sirtuins to remove acetyl groups. We predict
that histone acetyltransferase, which are enzymes that function to add acetyl groups are
involved as well. The exact molecular mechanisms and histone acetyltransferases’
involvement in the development of DOX-induced cardiotoxicity are still not completely
understood.

The goal of my research is to determine whether there are alternative compounds that can
prevent DOX-induced cardiotoxicity. In the first part of my research, I determined if
Nicotinamide mononucleotide (NMN) can protect against DOX using a heart cell line and
mouse models. NMN is another molecule that converts into NAD+ to activate histone
deacetylase. The second part of my project tests different histone acetyltransferase inhibitors
to examine whether they can protect a heart cell line from DOX. The histone
acetyltransferase inhibitor functions to block specific histone acetyltransferase members from
activating.
The findings from the first part of my research show that NMN increased NAD+ and
functions as a source of cardioprotection against DOX. The second portion of my study
shows that specific histone acetyltransferase family members are not involved in DOXiii

induced cardiotoxicity. Hence, my research contributes to advancing current scientific
knowledge in the field of DOX-induced cardiotoxicity and discovering preventive
therapeutics options for millions of cancer patients.
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Chapter 1

1

Introduction

Cancer is one of the leading causes of death worldwide. According to the World Health
Organization, there will 10-11 million new cancer cases diagnosed annually by 2030 (1).
Chemotherapy is a widely used treatment option for patients at different cancer stages to
prevent cancer cell proliferation. Anthracyclines are a class of drugs that include
Doxorubicin and are one of the most effective types of chemotherapy (2).

1.1 Doxorubicin
Doxorubicin (DOX), under the brand name Adriamycin, is a first line chemotherapeutic
given to children and adults with various cancer types such as breast cancer or leukemias
(3). DOX was discovered in the 1960’s by Italian researchers isolating anti-cancer
compounds produced by soil microbes (4). Researchers found that colonies of
Streptomyces peucetius produced red pigments with antibiotic properties and named the
compound Daunomycin (4). After discovering that a French research group isolated the
same compound, the compound became known as Daunorubicin. Daunorubicin
eventually was renamed DOX after a modification in the hydroxyl group on carbon 14
(4). The chemical structure of DOX contains an aglyconic moiety (tetracyclic ring with
quinine-hydroquinone adjacent groups, methoxy side chain, and carbonyl group) and
sugar component (also known as Daunosamine) (Figure 1) (5).
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Figure 1: Chemical Structure of Daunorubicin and DOX.
Daunorubicin and DOX structure differs in a hydroxyl group. The chemical formula of DOX is
C27H29NO11 and the molecular weight is 543.56 g/mol. The chemical formula of Daunorubicin is
C27H29NO10 and the molecular weight is 527.52 g/mol. Figure created using images from
WikiMedia Commons (6,7).

1.1.1

DOX’s mechanisms of action

As a member of the class I Anthracycline family, DOX is administered intravenously and
rapidly taken up by cells with an initial half-life of about 5 minutes (5,8). The terminal
half-life of DOX is between 20-48 hours from the tissue (8). DOX functions to initiate
cancer cell growth arrest through various mechanisms. One mechanism is through
intercalation between base pairs of double-stranded DNA to prevent DNA topoisomerase
II activity, which is required for DNA replication, transcription, and recombination (9).
DOX intercalates between the base pair of the DNA, resulting in disruption of DNA
topoisomerase II activity. Therefore, DNA replication is stopped, and cancer cells cannot
proliferate. Another mechanism is excessive reactive oxygen species (ROS) produced in
cells. DOX is oxidized from a quinone to semiquinone, an unstable metabolite to produce
free radicals following cellular uptake (10). The release of ROS leads to DNA damage,
oxidative stress, and cell death by apoptosis in cancer cells (11).

1.1.2

DOX-induced cardiotoxicity

The major problem with DOX is its detrimental side effects on the heart, leading to
serious cardiovascular complications such as heart failure and hypertension (12). Some
factors associated with increased risk of DOX-induced cardiotoxicity are being over the
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age of 65 (13,14), pre-existing cardiovascular diseases (13), gender as females are at a
higher risk (15,16) and DOX dosage. The total cumulative dose is the most critical risk
factor in predicting a patient’s likelihood of developing DOX-induced cardiotoxicity.
About 5% of adult patients experience congestive heart failure when receiving a
cumulative dose of 400 mg/m2 (14). The percentage increases to 26% when the
cumulative dose is 550 mg/m2 and further increases to 48% at a dose of 700 mg/m2 (14).
Even many years after stopping their DOX treatment, patients can still develop DOXinduced cardiotoxicity and its associated cardiovascular complications (12).

1.1.3

Treatment Options for DOX-induced cardiotoxicity

Patients with DOX-induced cardiotoxicity have been treated with drugs such as
Dexrazoxane, angiotensin-converting enzyme (ACE) inhibitor, β-blockers, and statins.
The only US Food and Drug Administration and Health Canada approved treatment for
DOX-induced cardiotoxicity is Dexrazoxane (17). Dexrazoxane functions a chelating
agent to reduce the metal ions that form with anthracyclines, thus reducing the generation
of ROS (18). However, it has been indicated that Dexrazoxane increases the risk of
developing a secondary malignancy in pediatric patients (19). A randomized
placebo‐controlled study found that ACE inhibitor, Enalapril reduced the early onset of
cardiac toxicity in children (20). Also, β-blockers have shown to be effective in
preventing DOX-induced cardiotoxicity in patients. For example, Carvedilol prevented
the decline of left ventricular ejection fraction in cancer patients (21). Statins can
decrease oxidative stress and inflammation caused by DOX. Breast cancer patients on
statins had a lower risk of heart failure compared to the non-statin treated group (22).
However, the long-term use of ACE inhibitors and β-blockers is associated with an
increased risk of cancer occurrence (23,24). More evidence about the success of these
drugs is required to fully understand their protective effects in patients.

1.1.4

DOX-induced cardiotoxicity’s mechanism of action

The exact mechanism in DOX-induced cardiotoxicity remains unknown. Multiple
mechanisms that have been reported to contribute to the development of DOX-induced
cardiotoxicity including generation of ROS (25), disruption of calcium ions (26), and
impairment of mitochondrial function (27). However, it has been suggested that ROS or
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oxidative stress may not be the primary mechanism leading to DOX-induced
cardiotoxicity (28). The precise molecular mechanism responsible remains unknown,
which makes it difficult to treat patients suffering from these cardiovascular
complications.
An emerging mechanism that has been proposed is the dysregulation in autophagy
leading to DOX-induced cardiotoxicity. Autophagy is a degradation process that
functions to engulf damaged protein and cellular organelles into an autophagosome (29).
Autophagic flux refers to the entire process that starts with the formation of
autophagosome, fusion with lysosomes to create autolysosomes, and breakdown of
molecules (29). A recent study suggests that DOX blocks autophagy by increasing the
lysosomal pH to become more basic, which disrupts the breakdown of unwanted cargo in
the autolysosomes (30). The accumulation of undegraded cargo leads to increased ROS
and results in cardiomyocyte death. By inducing autophagy, it should maintain
cardiomyocytes viability after DOX treatment (30). However, the literature presents
conflicting reports that DOX can induce excessive autophagy by upregulating initiation
genes (31,32). While others have demonstrated that inhibition of autophagy results in
increased ROS and accumulation of autolysosome leading to DOX-induced
cardiotoxicity (30,33,34). Thus, the involvement of autophagy and DOX-induced
cardiotoxicity is not clearly understood.

1.2 Nicotinamide adenine dinucleotide
Nicotinamide adenine dinucleotide (NAD+) is a pyridine nucleotide that is an essential
cofactor and substrate for multiple cellular processes (Figure 2). NAD+ is found in all
cells and plays a role production of cellular energy (adenosine triphosphate [ATP]),
glycolysis, and mitochondrial respiration (35). NAD+ can be produced from nicotinamide
(NAM), nicotinic acid, nicotinamide riboside (NR), and nicotinamide mononucleotide
(NMN).
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Figure 2: Chemical structure of NAD+.
The chemical formula of NAD+ is C21H27N7O14P2 and the molecular weight is 663.43 g/mol.
Figure from Wikimedia Commons (36).

NAM is a water-soluble amide form of vitamin B3 and is a precursor to NAD+ (37).
Nicotinic acid (also known as niacin) is also a form of vitamin B3 that is available in
food and supplements. Among the molecules that can synthesize NAD+, nicotinic acid
and NAM have several disadvantages compared to NR and NMN. Nicotinic acid and
NAM are associated with flushing (38) and may not activate sirtuins (39). Therefore,
NAM or nicotinic acid is not ideal as a therapeutic for patients. Also, NMN and NR are
preferred over the administration of NAD+ because NAD+ is less soluble and does not
effectively pass through the plasma membrane (40).
Many studies have shown that boosting NAD+ helps to combat diseases such as agerelated diseases (41) and diabetes (42). NAD+ is involved in regulating signalling
pathways for NAD+ dependent enzymes such as sirtuins (SIRTs) and Poly (ADP-ribose)
polymerase (PARP) enzymes (35). However, the role of NAD+ in cardiovascular health
has not been intensively investigated (43) despite that the concentration of NAD+ present
in the heart is the second highest, after the liver (44,45).
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1.2.1

Salvage NAD+ Pathway

NAD+ can be synthesized through 3 different pathways in mammalian cells. The first is
the de novo pathway which synthesizes NAD+ from tryptophan. The second pathway is
the salvage pathway that produces NAD+ from NAM, nicotinic acid, NR, or NMN.
Lastly, the Preiss-Handler pathway uses nicotinic acid and nicotinate
phosphoribosyltransferase (NAPRT) enzyme (46). In the heart, the majority of NAD+ is
synthesized through the salvage pathway (44,46) (Figure 3).
The salvage pathway recycles NAM from NAD+ consuming enzymes including SIRTs,
PARPs, and cyclic ADP-ribose synthases (CD38 and CD157) to produce NAD+ (47).
Nicotinamide phosphoribosyltransferase (NAMPT) recycles NAM into NMN, then NMN
is converted into NAD+ by various nicotinamide mononucleotide adenylyl transferases
(NMNATs) including NMNAT 1 in the nucleus, NMNAT 2 in the cytoplasm, and
NMNAT 3 in the mitochondria (47,48). NR enters the mammalian cell by equilibrative
nucleoside transporters (ENTs) and nicotinamide riboside kinases (NRK1/2)
phosphorylates NR into NMN (49–51). Then NMN gets converted into NAD+ by
NMNAT 1/2/3 in the body (49). Two mechanisms have been proposed for the conversion
of NMN to NAD+. First, the conversion of NMN into NAD+ requires a
dephosphorylation step by CD73 to convert into NR before entering the cell due to its
larger size, then converted into NMN by NRK1/2 (50). However, a recent study found
that the Solute carrier family 12 member 8 (Slc12a8) transporter allows for NMN to be
facilitated into the cell without being converted into NR by CD73 or NRK1/2 (52).
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Figure 3: The salvage pathway to synthesizing NAD+.
The salvage pathway that produces NAD+ from NR, NMN, or NAM and the enzymes involved (blue). NR
can be transported into the cell by ENTs and converted NMN by NRK1/2. Once converted into NMN, it is
converted into NAD+ by NMNAT 1/2/3. NMN can be transported into the cell through the Slc12a8
transporter, then converted into NAD+ by NMNAT 1/2/3.

1.2.2

Nicotinamide Riboside

NR is a derivate of Vitamin B3 and transported into cells by ENTs (Figure 4). NR has
been reported to attenuate heart failure in mice by stabilizing NAD+ levels (53). In
humans, chronic oral NR supplementation effectively stimulated NAD+ metabolism,
reduced systolic blood pressure, and aortic stiffness (53). Also, pre-treatment with NR
protected against DOX-induced cardiotoxicity (54). After 24 hours of DOX treatment on
cardiomyocytes, there was increased caspase-3 activity, increased DNA fragmentation
indicating apoptosis, increased lactate dehydrogenase (LDH) release, and decreased cell
viability seen with DOX treatment (54). With the pre-incubation of NR for 24 hours
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before DOX treatment, the effects of DOX were lower compared to DOX treatment alone
(54). Furthermore, NR attenuated defects in myocardial function in DOX-injected mice
in a dose-dependent manner, which supports the indication of cardioprotective effects of
NR seen in the in vitro findings.

Figure 4: Chemical structure of NR.
The chemical formula of NR is C11H15N2O5 and the molecular weight is 255.25 g/mol. Figure
from Wikimedia Commons (55).

1.2.3

Nicotinamide Mononucleotide

NMN is another intermediate in NAD+ biosynthesis that can be produced from NAM and
phosphoribosyl pyrophosphates in cells (Figure 5). NMN is a source of cellular energy
and has a diverse range of functions, including cardioprotection and metabolism
regulation (48). NMN has its’ own advantage with several successful outcomes where
NR failed. For example, NMN treatment on Friedreich's ataxia knockout mice improved
diastolic function compared to saline control by increasing Silent mating type
information regulation 2 homolog 3 (SIRT3) activity (56). Exogeneous NMN protected
the heart against ischemia and reperfusion by decreasing FoxO1 acetylation and through
activating the Silent mating type information regulation 2 homolog 1 (SIRT1) pathway
(57). Also, it has been reported that NMN has a specific transporter, Slc12a8 that allows
for effective uptake into the circulation and tissues (52). A study revealed that NMN
increases heart tissue NAD+ to ameliorate DOX-induced dysfunction and improve
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myocardial dysfunction in p53 deficient mice (58). However, NMN has not been
extensively studied as a preventive treatment against DOX-induced cardiotoxicity.

Figure 5: Chemical structure of NMN.
The chemical formula of NMN is C11H15N2O8P and the molecular weight is the 334.22 g/mol.
Figure from Wikimedia Commons (59).

1.3 Histone Deacetylase Family
Histone deacetylases (HDACs) are enzymes that function to remove acetyl groups from
histones. The removal of the acetyl groups increases the positive histone tails to promote
high-affinity binding between histone and the DNA backbone (60). HDACs can have an
effect on non-histone proteins such as transcription factors (61). There are 18 mammalian
HDACs that are categorized into 4 different classes. First, Class I HDACs include HDAC
1, 2, 3, and 8, which have a Zinc dependent mechanism to deacetylase acetyl substrates
(62,63). The second group is Class II HDACs including HDACs 4, 5, 6, 7, 9, and 10,
which also utilize a Zinc dependent mechanism. Class II HDACs can be categorized into
2 subgroups, where are Class IIa including HDACs 4,5,7, and 9. The other subcategory is
Class IIb containing HDAC 6 and 10. The difference is that Class IIa has a large Cterminus while Class IIb contains 2 deacetylase domains. Class III HDACs contain
SIRTs 1-7, which are NAD+ dependent and requires NAD+ to transfer the acetyl group.
The last category is Class IV that only contains HDAC 11 and it is Zinc dependent
(62,63).
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1.3.1

SIRT1 and DOX-induced cardiotoxicity

SIRT1 and SIRT3 play an important role in maintaining cardiovascular physiology (64–
66). SIRT1 and SIRT3 functions as NAD+ dependent class III histone deacetylases.
Specifically, SIRT1 is highly expressed in cardiomyocytes and the NAD+/SIRT1
signaling pathway plays roles in metabolism, cellular energy maintenance, and longevity
(67). DOX decreased SIRT1 expression leading to DOX-induced myocardial apoptosis
(68). Pre-treatment with Resveratrol inhibited DOX-induced apoptosis in H9c2 cells
through activation of SIRT1 (68). The administration of the SIRT1 inhibitor (EX-527)
eliminated the protective effect of NR (54). This suggests that DOX interferes with
SIRT1’s regulation and the conversion of NR into NAD+ activates SIRT1 to provide
protection.

1.3.2

SIRT3 and DOX-induced cardiotoxicity

DOX treatment suppressed cardiac SIRT3 expression and is associated with higher
protein acetylation levels in H9c2 cells (64). Furthermore, overexpression of SIRT3
protected cardiomyocytes from DOX induced cell death (64). The mechanism of SIRT3
involves activation of NAD+ which alleviates hyperacetylation and attenuated cardiac
dysfunction (69). Therefore, HDAC specifically NAD+ consuming enzymes SIRTs plays
an important role in the development of DOX-induced cardiotoxicity.

1.4 Histone Acetyltransferase Family
The balance between acetylation and deacetylation is critical in maintaining various
cellular processes (70). Studies have proposed that the disbalance between histone
acetyltransferases (HATs) and HDACs activity contributes to cancers (71), inflammatory
diseases (72), and neurodegenerative disease (73). The increase in acetylation of various
molecular components has highlighted the importance of post-translational modifications
in DOX-induced cardiotoxicity. For example, DOX triggers increased p53 lysine
acetylation through the DNA damage repair pathway, thus upregulating p53 activity (74).
It has been observed that DOX decreases HDAC activity in cardiomyocytes and resulted
in increased p53 acetylation (54,75). When H9c2 cells were pre-treated with Trichostatin
A (TSA), a global HDAC inhibitor, it augmented DOX-induced cardiac hypertrophy and
DNA stranded breaks (61,76). Thus, the balance between acetylation and deacetylation is
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critical for cell survival in DOX-induced cardiotoxicity. However, the role of the HAT
family members has not been identified in DOX-induced cardiotoxicity.

HATs are enzymes on chromatin structures involved in transcription activation through
loosening chromatin to neutralize positively charged lysine. HATs are enzymes that
function to add an acetyl group on histone and non-histone proteins (77). HATs are
categorized into 2 types, Type A HATs and Type B HATs. Type A HATs are mainly
nuclear and can be subclassified into 5 groups. The first group is the GCN5-related
acetyltransferases (GNAT) containing General Control Nonderepressible (GNC5),
p300/CBP associated factor (PCAF), and Elongator complex protein (ELP3). The second
group is p300/CBP consisting of p300 and CREB-binding protein (CBP). The third group
is called the MOZ, YBF2/SAS3, SAS2, and TIP60 protein (MYST) family containing
MYST1 (HMOF), MYST2 (HB01), MYST3 (MOZ), MYST4 (MORF) and tat
interacting protein 60 kDa (TIP60). The fourth group is the basal Transcription factor
family including Transcription Factor IIIC and Tat-interactive protein 60 kDa (TAF1).
Lastly are the nuclear receptor cofactors (NRCF) family with steroid receptor coactivator
(SRA) and nuclear receptor coactivator 3 (NCOA3/ACTR) (78).

Type B HATs are referred to as cytoplasmic HATs because they are responsible for
modifying free histone in the cytoplasm. The family contains HAT1, HAT2, Rtt109,
HatB3.1, and HAT4 (78). Specifically, Type A HATs are of interest because of their
ability to function as acetyltransferase for histone and non-histone targets including
SIRT2 (79).

1.4.1

GCN5 and Butyrolactone 3 inhibitor

GCN5/PCAF can acetylate non-histone proteins such as tumour suppressors (80) and
numerous transcription factors (81). It contains a HAT domain that is about 160 resides
with a conserved bromodomain (82). One of the HAT inhibitors used in this study is
Butyrolactone 3, which is a GCN5 inhibitor with an IC50 value of 100 μM (Figure 6) (4).
Butyrolactone 3 (also called MB-3) inhibits HAT GCN5 and derived from γ-
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Butyrolactones, class of metabolites from the Aspergillus genus (83). There are no
published studies examining the effect of Butyrolactone 3 in cardiovascular research.

Figure 6: Chemical structure of Butyrolactone 3.
The chemical formula of Butyrolactone 3 is C9H12O4 and the molecular weight is 184.19 g/mol.
Figure from Mai et al., (84).

1.4.2

TIP60 and MG149 inhibitor

TIP60 is a member of the MYST family and plays a critical role in a wide range of
cellular processing such as cell growth and transcription (85). TIP60 protein is required
for cardiomyocyte vitality and survival (86). Also, TIP60 is highly expressed in
cardiomyocytes and contributes to autophagy regulation (87). To identify the role of
TIP60 in this study, we used MG149, a TIP60 inhibitor at an IC50 values of 74 μM (88)
(89) derived from anacardic acid (90) (Figure 7).
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Figure 7: Chemical structure of MG149.
The chemical formula for MG149 is C22H28O3 and the molecular weight is 340.46 g/mol. Figure
from MedChemExpress (91).

1.4.3

p300/CBP, C646, and HAT inhibitor II

The p300/CBP family consists of related proteins p300 and CBP, which have a similar
structure containing a HAT domain that is about 500 residues with 86% sequence
identity, a bromodomain, and 3 cysteine-histidine rich domains (92). p300 and CBP are
involved in physiological processes including cell survival, maintaining cardiac
mitochondrial function (93), differentiation, and growth of cardiomyocytes (94). A study
revealed that HAT inhibitor, Spermidine was able to induce autophagy by inhibiting p300
activity which was associated with decreased acetylation levels and increase autophagic
flux (95).

In this study, we used HAT inhibitor II, which is a novel selective inhibitor for p300
(Figure 8) (96). HAT II inhibitor is a cyclohexanone derivative and inhibits p300 with
IC50 values ranging from 5-233 μM (96). Another small molecule inhibitor for p300/CBP
used in this study is C646 with an IC50 value of 1.6 μM (Figure 9) (97). A diagram of the
HAT inhibitors used in this study and its associated HAT target can be seen in Figure 10.
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Figure 8: Chemical structure of HAT inhibitor II.
The chemical formula of HAT inhibitor II is C20H16Br2O3 and the molecular weight is 464.15
g/mol. Figure from Costi et al., (96).

Figure 9: Chemical structure of C646.
The chemical formula of C646 is C24H19N3O6 and the molecular weight is 445.42 g/mol. Figure
from Bowers et al., (97).
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Figure 10: Diagram of the HAT family members and inhibitors used in this study.
The pharmacological inhibitors that have been used in this study shown to inhibit the targeted
HAT family member.

Table 1: Summary of the chemical structure, formula, and function of key biological
and chemical molecules.
Name
Chemical
Molecular
Function
Structure
Weight
(g/mol)
DOX
C27H29NO11
543.56
Chemotherapy
+
NAD
C21H27N7O14P2
663.43
Cofactor
involved in
various cellular
processes
NR
C11H15N2O5
255.25
Precursor to
NAD+
NMN
C11H15N2O8P
334.22
Precursor to
NAD+
Butyrolactone 3
C9H12O4
184.19
GCN5
inhibitor
MG149
C22H28O3
340.46
TIP60 inhibitor
HAT inhibitor II
C20H16Br2O3
464.15
p300 inhibitor
C646
C24H19N3O6
445.42
p300/CBP
inhibitor
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1.5 Proposed Model
We proposed that DOX-induced toxicity onto cardiomyocytes by reducing NAD+
concentration in the cells (Figure 11). The low concentration of NAD+ impacts SIRTs’
activity leading to increased acetylation levels in the cells. The increased acetylation
impairs autophagy and is associated with the accumulation of undegraded cargo. Thus, it
results in cardiomyocyte cell death. By increasing NAD+ with NMN, SIRTs activity will
increase, thereby prevent acetylation and protection from cell death. Alternatively,
preventing acetylation using a small molecular HAT inhibitor can decrease acetylation
levels to prevents cardiomyocytes cell death.

Figure 11: Proposed Model of DOX-induced cardiotoxicity.
DOX impacts NAD+ concentration in cardiomyocytes. The low concentration of NAD+ impacts
SIRTs’ activity leading to increased protein acetylation levels in the cells. The increased
acetylation impairs autophagy and eventually results in cardiomyocyte cell death. By increasing
NAD+ with NMN, SIRTs activity will increase thereby prevent acetylation and protecting cells
from death.

17

1.6 Hypothesis
It is hypothesized that administrating NMN to increase cellular NAD+ concentration or
HAT inhibitors to prevent protein acetylation will protect cells against DOX-induced
cardiotoxicity.

1.7 Specific Aims
1.7.1

To evaluate the utility of H9c2 cell culture as an in vitro
model to study DOX-induced cardiotoxicity

Rationale for Aim 1: The H9c2 cell line was derived from embryonic rats’ ventricular
heart tissue. The H9c2 cells exhibit similar membrane morphology and
electrophysiological properties to primary cardiomyocytes (98). The purpose of this
objective is to confirm the utility of H9c2 cell culture to study DOX-induced
cardiotoxicity and to ensure that DOX induces H9c2 cell death in a dose-dependent
manner.

1.7.2

To determine if NMN protects against DOX-induced
cardiotoxicity through boosting cellular NAD+ concentration in
H9c2 cells and adult mice hearts

Rationale for Aim 2: Our laboratory revealed that the administration of NR prevented
DOX-induced cardiotoxicity (54). The protective effect of NR involved converting into
NAD+, then activation of SIRT1 to prevent DOX-induced cardiotoxicity in both neonatal
cardiomyocytes and adult mouse tissue (54). To further investigate the role of NAD+ and
the other NAD+ precursors, I administered NMN to determine if NMN can protect
against DOX-induced cardiotoxicity on H9c2 cells and adult mice.

1.7.3

To examine the effect of pharmacological HAT inhibitors on
DOX-induced cardiotoxicity

Rationale for Aim 3: Our previous research revealed that DOX interferes with SIRTs
regulation and inhibition of HDAC with TSA increased DOX damage (75). Since
HDACs are involved in protecting against DOX-induced cardiotoxicity, I aim to
determine if HATs are involved in this process. Therefore, the goal of this objective is to
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examine if HAT inhibitors play a role in protecting against DOX-induced damage in
H9c2 cells.
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Chapter 2

2

Material and Methods

2.1 Cell Culture
The H9c2 cell line was purchased from the American Type Culture Collection.
H9c2 cells were grown and maintained in High Glucose Dulbecco’s Modified
Eagle Medium (DMEM; Gibco, Waltham, Massachusetts), 1% penicillinstreptomycin (P/S, 10000 IU penicillin, 10000 μg/mL streptomycin; Gibco,
Waltham, Massachusetts), and 10% heat-inactivated fetal bovine serum (FBS;
Thermo Fisher Scientific, Waltham, Massachusetts) at 37°C in a 5% CO2
incubator.

When passaging the cells, 3 mL of D-Hank's solution (Table 2) was used to wash
the cells for 30 seconds at room temperature. Then, 1.5 mL of 0.25% Trypsin (2.21
mM EDTA; Wisent Bioproducts, Saint-Jean-Baptiste, Quebec) was added into the
flask and placed into the 37°C incubator for 60 seconds. Six mL of DMEM
containing 1% P/S and 10% FBS was added into the flask to terminate the
trypsinization process. After terminating the trypsinization, cells were collected
into a 12 mL tube and centrifuged at 200 rpm for 5 minutes.

When seeding the cells, the same steps for passaging the cells were performed. The
supernatant was removed and 6 mL of fresh DMEM containing 1% P/S and 10%
FBS at 37°C was added into the flask. Cells were counted using a hemocytometer
for the subsequent assays.

For cell cryopreservation, cells were passaged and the supernatant was removed.
Then 900 μL of 10% FBS and 100 μL of dimethyl sulfoxide (DMSO; Bio Basic,
Markham, Canada) were added into the 12 mL tube. A transfer pipette was used to
suspend the cell in the solution. The solution was transferred into a 1.5 mL tube
and placed into a -80°C freezer. To thaw cells, the frozen 1.5 mL tube containing
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cells was removed from the -80°C freezer and placed into a 37°C water bath for 30
seconds. Then, the solution was added into a T25 flask with 5 mL of DMEM
containing 1% P/S and 10% FBS.
Table 2: Components in 1L of D-Hanks’ solution
Component
D-Glucose
Potassium chloride (KCl)
Potassium Dihydrogen Phosphate
(KH₂PO₄)
Sodium chloride (NaCl)
Phenol red

Amount
1.000 g
0.400 g
0.060 g
8.000 g
0.012 g

2.2 Caspase-3 Activity Measurement
Caspase-3 activity was measured as an indicator of apoptosis after cell treatment.
The culture media in each well was removed, then 100 μL of lysis buffer (Table 3)
was added into each well. A cell scraper was used to detach cells from the plate.
The cells were collected into 1.5 mL tubes and centrifuged at 10,000 rpm for 7
minutes at 4°C. The Bradford assay was used to determine the protein
concentration of the supernatant. Afterward, in a 96-black well plate, 150 μg of
protein was incubated in the assay buffer (Table 4) with Ac-DEVD-AMC
(Cayman Chemical, Ann Arbor, Michigan) and Ac-DEVD-CHO (Cayman
Chemical, Ann Arbor, Michigan) or Ac-DEVD-AMC only for 3 hours at 37°C.
The measurement for caspase-3 activity was recorded on a fluorescent
spectrophotometer every 30 minutes for 4 hours at an excitation of 355 nm and an
emission of 460 nm. Caspase-3 activity is measured as fluorescence intensity
values and presented as relative fold changes to the control value in the results.
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Table 3: Components in 100 mL of Caspase-3 Lysis Buffer.
Component
CHAPS
DTT
EDTA
HEPES (pH 7.4)
NP-40
H2O

Amount/Volume
0.1 g
500.0 μL
20.0 μL
5.0 mL
100.0 μL
94.4 mL

Table 4: Components in 100 mL of Caspase-3 Assay Buffer.
Component
CHAPS
DTT
EDTA
Glycerol
HEPES (pH 7.4)
NaCl
H2O

Amount/Volume
0.1 g
1.0 mL
200.0 μL
10.0 mL
5.0 mL
585.0 mg
83.8 mL

2.3 Lactate Dehydrogenase Release Assay from Clontech
The colorimetric kit was used according to the manufacturer’s instructions
(Clontech, Mountain View, California) to detect LDH activity released in the
supernatant when NAD+ was reduced to NADH+. For each well, 50 μL of the
sample and 50 μL of the LDH reaction mixture were added into a transparent 96well plate. Readings were taken after 15 minutes of adding the reaction mixture
and measured at 490 nm in a microplate reader. LDH release is measured as
absorbance values and presented as relative fold changes to the control value in the
results.

2.4 NAD+ Microplate Reader Assay from Cohesion
Biosciences
To detach and collect the cells for the NAD+ concentration assay, 500 μL of 0.25
% Trypsin was added into each well for 30 seconds. Then, 1.5 mL of DMEM with
1% P/S and 10% FBS was added into each well to terminate the trypsinization
process. Cells were collected into a 2 mL tube and centrifuged at 1000 rpm for 5
minutes at 4°C. The supernatant was removed, then the NAD+ concentration was
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extracted and measured according to the NAD/NADH Microplate Assay Kit
manufacturer’s instructions (Cohesion Biosciences, Burlington, Ontario). The
readings for the assay were measured at 550 nm using a microplate reader. NAD+
concentration is measured as absorbance values and presented as relative fold
changes to the control value in the results.

2.5 Caclein AM Cell Viability Assay from Trevigen
To assess cell viability, 2 washes of 100 μl of 1X calcein AM DW Buffer was
performed before 1 μM calcein was used to stain the cells. All other steps of the
assay were used following to manufacturers’ instructions (Trevigen, Gaithersburg,
Maryland). The readings were measured every 10 minutes for 30 minutes using a
fluorescent spectrophotometer at 480 nm excitation and 520 nm emission. Calcein
AM cell viability is measured as fluorescence intensity values and presented as
relative fold changes to the control value in the results.

2.6 Animals
Experimental procedures were approved by the Animal Use Subcommittee at the
University of Western in Ontario, Canada (Animal Use Protocol #2016-059). The
animal studies were conducted at Victoria Research Laboratories of Lawson
Health Research Institute. The breeding pairs of C57BL/6 mice were purchased
from the Jackson Laboratory. All animals were housed in a temperature and
humidity-controlled facility with water and food.

2.7 Echocardiography
We established 4 groups including vehicle control, NMN control, DOX vehicle, and
NMN with DOX group. Each group contained 5 three-month-old C57BL/6 male mice
reared under the same conditions. Mice were injected with either NMN (500 mg/kg, i.p.)
or saline. Thirty minutes later, the mice received a DOX (20 mg/kg, i.p.) or saline
injection. After 5 days, animals were anesthetized with 1% inhaled isoflurane. Then, the
mice were placed into handling platform and imaged with a 40-MHz linear array
transducer using a pre-clinical ultrasound system (Vevo 2100, Visual Sonics, Canada)
and nominal in-plane spatial resolution of 40 μM (axial) by 80 μM (lateral). Pulsed wave

23

Doppler measures of maximal early and late transmitral velocities in diastole were
collected at the apical view (cursor at mitral valve inflow). The changes to the LVIDd,
LVIDs, ejection fraction (EF) percentage, and fractional shortening (FS) percentage was
analyzed on M-mode scans at the 2D parasternal short axis.
The EF is the volumetric fraction of blood pumped from the left ventricle (LV) at each
beat. The EF% is calculated by the equation,
𝐿𝑉 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑣𝑜𝑙𝑢𝑚𝑒 − 𝐿𝑉 𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑣𝑜𝑙𝑢𝑚𝑒
) 𝑥100
𝐸𝐹% = (
𝐿𝑉 𝑑𝑖𝑠𝑡𝑜𝑙𝑖𝑐 𝑣𝑜𝑙𝑢𝑚𝑒
The FS is the measurement of change in the LV diameter. The FS % is calculated by the
equation,
𝐹𝑆% = (

𝐿𝑉𝐼𝐷𝑑 − 𝐿𝑉𝐼𝐷𝑠
) 𝑥100
𝐿𝑉𝐼𝐷𝑑

2.8 Evans Blue Staining
Four groups including vehicle control, NMN control, DOX vehicle, and NMN
with DOX group was established. Each group contained 5 three-month-old
C57BL/6 male mice. Mice were injected with either NMN (500 mg/kg, i.p.) or
saline. After 30 minutes, the mice received a DOX (20 mg/kg, i.p.) or saline
injection. Five days later, Evan Blue dye (100 mg/kg, i.p.) was dissolved in 1X
Phosphate-buffered saline (PBS; Table 5), then injected into all of the mice. Four
hours later, mice were euthanized by cervical dislocation and the hearts were
collected. The hearts were embedded into the optimal cutting temperature
compound (Sakura Finetek, Torrance, California) and placed into a -80°C freezer.
The frozen tissue was cut into 6 μM thickness cryosections, stained with 8 μL of 1
mg/mL of Hoechst 33342 (Invitrogen, Carlsbad, California) for 20 minutes, and
mounted with 10 μL fluorescence mounting medium (Agilent Technologies Santa
Clara, California).
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Cell membrane permeability to Evans Blue dye was visualized under a
fluorescence microscope and positive cells were captured on 10x and 40x
objective. The percentage of positive cell staining was estimated using 20 different
images for each treatment group (5 samples x 4 images per sample; totaling at least
6000 nuclei) captured on 10x with the ImageJ software. The results are presented
as the estimated percentage of positive cells stained with Evan Blue relative to the
total nuclei stained.
Table 5: Components in 1L of 1X PBS.
Component
KCl
KH₂PO₄
NaCl
Sodium Phosphate Dibasic (Na₂HPO₄)
H2O

Amount/Volume
0.20 g
0.24 g
8.00 g
1.44 g
995 mL

2.9 Solution preparation
2.9.1

DOX

A stock concentration of 1 mM DOX was created by dissolving 0.0011 g of DOX
(Hospira, London, Ontario) into 2 mL of sterilized H2O. The solution was mixed until it
was uniformly distributed. The stock solution was stored at 4 °C for up to 1 month. The
working concentration of DOX (1, 2, or 5 μM) was created using 1 mM of DOX and
diluted with DMEM containing 1% P/S and 10% FBS.

2.9.2

NMN

A stock concentration of 10 mM NMN was created by dissolving 0.001 g of NMN
(Apexbio Technology, Burlington, Ontario) into 299 μL of sterilized H2O. The solution
was mixed until it was evenly distributed. The stock solution was stored at -20°C for up
to 6 months. The working concentration of 500 μM NMN was created using the 10 mM
of NMN and diluted with DMEM containing 1% P/S and 10% FBS.
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2.9.3

NAD+ free acid

A stock concentration of 10 mM NAD+ free acid was created by dissolving 0.0019 g of
NAD+ free acid (Calbiochem, Oakville, Ontario) into 286 μL of sterilized H2O. The
solution was mixed until it was uniformly distributed. The stock solution was stored at 20°C for up to 6 months. The working concentration of 500 μM NAD+ free acid was
created using the 10 mM of NAD+ free acid and diluted with DMEM containing 1% P/S
and 10% FBS.

2.9.4

Butyrolactone 3

A stock concentration of 200 mM Butyrolactone 3 was created by dissolving 5 mg of
Butyrolactone 3 (Cayman Chemicals, Ann Arbor, Michigan) into 135 μL of DMSO (Bio
Basic, Markham, Canada). The solution was mixed until it was uniformly distributed.
The stock solution was stored at -20°C for up to 12 months. The working concentration
of (50 or 100 μM) Butyrolactone 3 was created using the 200 mM of Butyrolactone 3 and
diluted with DMEM containing 1% P/S and 10% FBS.

2.9.5

MG149

A stock concentration of 10 mM MG149 was created by dissolving 1 mg of MG149
(Cayman Chemicals, Ann Arbor, Michigan) into 293 μL of DMSO (Bio Basic, Markham,
Canada). The solution was mixed until it was evenly distributed. The stock solution was
stored at -20°C for up to 12 months. The working concentration of 10 μM MG149 was
created using the 10 mM of MG149 and diluted with DMEM containing 1% P/S and 10%
FBS.

2.9.6

C646

A stock concentration of 10 mM C646 was created by dissolving 1 mg of C646 (Cayman
Chemicals, Ann Arbor, Michigan) into 224 μL of DMSO (Bio Basic, Markham, Canada).
The solution was mixed until it was evenly distributed. The stock solution was stored at 20°C for up to 12 months. The working concentration of (2, 10, or 30 μM) C646 was
created using the 10 mM C646 and diluted with DMEM containing 1% P/S and 10%
FBS.
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2.9.7

HAT inhibitor II

A stock concentration of 10 mM HAT inhibitor II was created by dissolving 1 mg of
HAT inhibitor II (Cayman Chemicals, Ann Arbor, Michigan) into 215 μL of DMSO (Bio
Basics, Toronto, Canada). The solution was mixed until it was uniformly distributed. The
stock solution was stored at -20°C for up to 12 months. The working concentration of (5
or 10 μM) HAT inhibitor II was created using the 10 mM of HAT inhibitor II and diluted
with DMEM containing 1% P/S and 10% FBS.

2.10 Data Analysis
The data are provided as mean values ± SD. A one-way ANOVA analysis
followed by the Bonferroni test was performed. All statistical analyses were
performed using GraphPad Prism 8. A statistical significance was defined by *pvalue ≤0.05, ** p-value ≤ 0.01, ***p-value ≤0.001, and ****p-value≤ 0.0001.
Table 6: List and descriptions of reagents.
Name
Ac-DEVD-AMC
Ac-DEVD-CHO
Bradford Assay
Butyrolactone 3
C646
CHAPS
DAKO Fluorescence
Mounting Medium
D-glucose
DMEM
DMSO
DOX
DTT
EDTA
Evans Blue dye

FBS

Description
Caspase-3
fluorogenic substrate
Caspase 3/caspase-7
inhibitor
Measure protein
concentration
GNC5 inhibitor
p300/CBP inhibitor
Chemical reagent
Visualization of
specimens
Chemical reagent
Cell culture media
Organic reagent
Chemotherapy drug
Chemical reagent
Chemical reagent
Non-permeating dye
to check cell
viability
Growth factors and

Source (Catalog
Number)
Cayman Chemicals (14986)
Cayman Chemicals (10017)
Bio-Rad (500-0001)
Cayman Chemicals (12095)
Cayman Chemicals (10549)
Bio Basic (CD0110)
Agilent Technologies
(S3023)
Bio Basic (GB0219)
Gibco (11965092)
Bio Basic (DC4103)
Hospira (02194465)
Bio Basic (DB0058)
Sigma (E5134)
Invitrogen (314136)

Thermo Fisher Scientific
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Glycerol
HAT inhibitor II
HEPES
Hoechst 33342
KCl
KH2PO4
MG149
Na2HPO4
NaCl
NAD+ free acid
NMN
NP-40
P/S
Phenol red
Tissue-Tek Optimal
cutting temperature
compound
Trypsin

supplements for cell
culture
Chemical substance
p300 inhibitor
Buffering agent
Nucleic acid stain
Chemical reagent
Chemical reagent
TIP60 inhibitor
Chemical reagent
Chemical reagent
Chemical cofactor
for enzyme
Intermediate of
NAD+
Detergent
Antibiotic penicillin
and streptomycin
pH indicator
Compound to embed
tissue sample

(16000044)

Cell dissociation
reagent

Wisent Bioproducts
(325-043-EL)

Sigma (G5516)
Cayman Chemicals (19835)
Bio Basic (HB0264)
Invitrogen (H3570)
Sigma (PX1405-1)
Bio Basic (PB0445)
Cayman Chemicals (22135)
Sigma (S0876)
Bio Basic (DB0483)
Calbiochem (481911)
Apexbio Technology
(B7878)
Sigma (13021)
Gibco (15140122)
Sigma (P5530)
Sakura Finetek (4583)
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3

Results

3.1 DOX increases LDH release in a dose-dependent
manner
Cell death encompasses different types of cellular processes including necrosis and
apoptosis. My first cell death assays involved detecting LDH, which is a cytoplasmic
enzyme released into the culture media and a measure of necrosis. I cultured H9c2 cells
in 24-well plates at a seeding density of 2.0x104 cells per well, then treated cells with
either 1, 2, or 5 μM of DOX for 24 hours. One μM of DOX resulted in higher LDH by
approximately 30%, while 2 μM of DOX resulted in higher LDH by 90% compared to
the control group. At 5 μM of DOX, there was an increase of 160% in LDH release
compared to control (Figure 12). Therefore, DOX induces LDH release in a dosedependent manner.

Figure 12: Effect of DOX on LDH release in H9c2 cells.
H9c2 cells were treated with 1, 2, and 5 μM of DOX for 24 hours in culture media. LDH levels
were determined from the culture media. Data are provided as means ± SD. A one-way ANOVA
analysis followed by the Bonferroni test was performed. A statistical significance was defined by
*p-value ≤ 0.05, ***p-value ≤ 0.001, and ****p-value ≤ 0.0001.
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3.2 DOX increases caspase-3 activity in a dose-dependent
manner
Apoptosis is another method of cell death. To differentiate between necrosis and
apoptosis, I detected caspase-3 activity as a measure of apoptosis. I cultured H9c2 cells in
24-well plates at a seeding density of 2.0x104 cells per well, then treated cells with either
1, 2, or 5 μM of DOX for 24 hours. To collect the cells, I added a lysis buffer (Table 3)
and scraped the cells off the plate for the caspase-3 activity assay. One μM of DOX
resulted in higher caspase-3 activity by approximately 90%, while 2 μM increased
caspase-3 activity by 9-fold compared to the control group. At 5 μM of DOX, caspase-3
activity was 14-fold higher than the control group (Figure 13). Therefore, DOX-induced
caspase-3 activity in a dose-dependent manner.

Figure 13: Effect of DOX on caspase-3 activity in H9c2 cells.
H9c2 cells were treated with 1, 2, and 5 μM of DOX for 24 hours in culture media. Apoptosis
was determined by caspase-3 activity. Data are provided as means ± SD. A one-way ANOVA
analysis followed by the Bonferroni test was performed. A statistical significance was defined by
*p-value ≤ 0.05 and ****p-value ≤ 0.0001.
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3.3 DOX reduces H9c2 cells viability in a dose-dependent
manner
To further understand DOX’s effect on H9c2 cells, I determined H9c2 cell viability using
calcein AM, a compound that will produce a strong fluorescent compound in live cells.
The advantage of utilizing this technique is that I can image the live cell with a
fluorescent microscope and capture the quantitative measurement within 2 hours. I
cultured H9c2 cells in 96-well plates at a seeding density of 2.0x103 cells per well then
treated cells with either 1, 2, or 5 μM of DOX for 24 hours.
The results showed that 1 μM of DOX decreased H9c2 cell viability by 25% compared to
the control. While increasing to 2 μM resulted in lower cell viability by 35% compared to
the control group. At 5 μM of DOX, cell viability was 40% lower compared to the
control (Figure 14). Therefore, DOX decreased H9c2 cell viability in a dose-dependent
manner.
My results revealed that DOX induces damage onto H9c2 cells in a dose-dependent
manner as determined by the LDH release, caspase-3 activity, and cell viability
experiments. Based on these findings, I decided to use 1 μM of DOX for subsequent
experiments on H9c2 cells since that dose can induce sufficient damage to H9c2 cells.
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Figure 14: Effect of DOX on H9c2 cells viability.
H9c2 cells were treated with either DOX at 1, 2, and 5 μM on H9c2 cells for 24 hours in culture
media. The graph shows the quantitative data of cell viability measured with 1 μM of calcein
AM. Data are provided as means ± SD. A one-way ANOVA analysis followed by the Bonferroni
test was performed. A statistical significance was defined by ****p-value ≤ 0.0001.
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3.4 DOX treatment results in lower NAD+ concentration in
H9c2 cells
To determine the effect of DOX on NAD+, I measured the NAD+ concentration after
DOX treatment. I seeded H9c2 cells in a 24-well plate at a seeding density of 2.0x104 per
well. Then, I pre-incubated the cells with either vehicle or DOX for 24 hours in culture
media. After treatment with DOX, I collected the cells and measured the NAD+
concentration using a commercially available kit from Cohesion Biosciences. I found that
the DOX treated group had a 20% lower NAD+ concentration compared to the control
group (Figure 15).

Figure 15: NAD+ concentration after treatment with DOX in H9c2 cells.
NAD+ concentration of H9c2 cells after treatment with 1 μM of DOX for 24 hours or 500 μM of
NMN for 18 hours in culture media. Data are provided as means ± SD. A one-way ANOVA
analysis followed by the Bonferroni test was performed. A statistical significance was defined by
***p-value ≤ 0.001.
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3.5 NMN treatment results in higher NAD+ concentration in
H9c2 cells
To ensure that NMN is converted into NAD+, I measured the NAD+ concentration after
NMN treatment. I seeded H9c2 cells in a 24-well plate at a seeding density of 2.0x104 per
well. Then, I pre-incubated the cells with either NMN (500 μM) or vehicle for 18 hours
in culture media. After treatment with NMN, the cells were collected and NAD+
concentration was measured using a commercially available kit from Cohesion
Biosciences. The result revealed that pre-incubating H9c2 cells with NMN resulted in a
17% higher NAD+ concentration compared to the vehicle treated group (Figure 16).

Figure 16: NAD+ concentration after treatment with NMN in H9c2 cells.
NAD+ concentration of H9c2 cells after treatment with 1 μM of DOX for 24 hours or 500 μM of
NMN for 18 hours in culture media. Data are provided as means ± SD. A one-way ANOVA
analysis followed by the Bonferroni test was performed. A statistical significance was defined by
*p-value ≤ 0.05.
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3.6 NMN abrogates LDH release in H9c2 cells
I measured the LDH release of cells pre-treated with NMN to determine damage by
DOX. I seeded H9c2 cells in a 24-well plate at a seeding density of 2.0x104 cells per
well. I pre-incubated cells with either vehicle or NMN for 18 hours, then treated cells
with DOX for 24 hours in culture media. After treatment with DOX, I collected
supernatant and measured the LDH release. The results revealed that cells treated with
500 μM of NMN had about 30% lower LDH release than DOX treated cells (Figure 17).
The level of LDH release in the pre-incubated group with NMN was similar to that in the
control group, which suggests that NMN can prevent the increased LDH release caused
by DOX.

Figure 17: Effect of NMN on LDH release in H9c2 cells.
H9c2 cells pre-incubated with vehicle or 500 μM of NMN for 18 hours in culture media, then 1
μM of DOX for 24 hours. LDH release was determined using the culture media. Data are
provided as means ± SD. A one-way ANOVA analysis followed by the Bonferroni test was
performed. A statistical significance was defined by **p-value ≤ 0.01.
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3.7 NMN abrogates caspase-3 activity in H9c2 cells
I measured caspase-3 activity as an indicator of apoptosis. I seeded H9c2 cells in a 24well plate at a seeding density of 2.0x104 cells per well. Then, I pre-incubated cells with
either vehicle or NMN for 18 hours, then treated cells with DOX for 24 hours in culture
media. The results revealed that pre-incubation with 500 μM of NMN before DOX
treatment resulted in a 60% reduction in caspase-3 activity compared to the DOX
treatment alone (Figure 18).

Figure 18: Effect of NMN on caspase-3 activity in H9c2 cells.
H9c2 cells pre-incubated with vehicle or 500 μM of NMN for 18 hours, then 1 μM of DOX for
24 hours in culture media. Caspase-3 activity was determined. Data are provided as means ± SD.
A one-way ANOVA analysis followed by the Bonferroni test was performed. A statistical
significance was defined by **p-value ≤0.01 and ****p-value ≤ 0.0001.
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3.8 NMN abrogates DOX-induced loss of H9c2 cell viability
I measured the cell viability using the calcein AM to determine if NMN can block the
loss of cell viability caused by DOX. I seeded H9c2 cells in a 96-well plate at a seeding
density of 2.0x103 cells per well. Then, I pre-incubated cells with either vehicle or NMN
for 18 hours, then treated cells with DOX for 24 hours in culture media. The result
revealed that pre-incubaton with 500 μM of NMN abrogated H9c2 cell viability by about
10% compared to the DOX treated group (Figure 19).

Figure 19: Effect of NMN on DOX-induced loss of H9c2 cell viability.
H9c2 cells pre-incubated either with vehicle or 500 μM of NMN for 18 hours, then 1 μM of DOX
for 24 hours in culture media. Cell viability was measured using 1 μM of calcein AM. Data are
provided as means ± SD. A one-way ANOVA analysis followed by the Bonferroni test was
performed. A statistical significance was defined by *p-value ≤ 0.05, ****p-value ≤ 0.0001,
n.s=not significant.
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3.9 NAD+ free acid abrogates DOX-induced death in H9c2
cells
I have shown that DOX decreases NAD+ concentration and pre-incubated cells with
NMN boosted NAD+ in cells (Figure 14). The purpose of this experiment is to determine
whether NAD+ free acid can reduce DOX-induced loss of H9c2 cell viability. I seeded
H9c2 cells in a 96-well plate at a seeding density of 2.0x103 cells per well. Cells were
treated either with vehicle or NAD+ free acid for 1 hour, then DOX for 24 hours. When
H9c2 cells were pre-incubated with NAD+ free acid, there was about 10% higher cell
viability compared to the DOX treated group (Figure 20).

Figure 20: Effect of NAD+ free acid on DOX-induced cell death in H9c2 cells.
H9c2 cells pre-incubated with either vehicle or 500 μM of NAD+ for 1 hour, then 1 μM of DOX
for 24 hours in culture media. Cell viability was measured using 1 μM of calcein AM. Data are
provided as means ± SD. A one-way ANOVA analysis followed by the Bonferroni test was
performed. A statistical significance was defined by *p-value ≤ 0.05, ***p-value ≤ 0.001, and
n.s=not significant.
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3.10 NAD+ free acid decreases caspase-3 activity in H9c2
cells treated with DOX
Since the cell viability assay suggests that NAD+ free acid provided protection against
DOX, I wanted to assess caspase-3 activity. I seeded H9c2 cells in a 24-well plate at a
seeding density of 2.0x104 cells per well. Cells were treated either with vehicle or NAD+
free acid for 1 hour, then DOX for 24 hours. The results showed that cells pre-treated
with 500 μM of NAD+ free acid had about 50% lower caspase-3 activity in comparison to
the DOX treated group (Figure 21).

Figure 21: Effect of NAD+ free acid on caspase-3 activity in H9c2 cells treated with
DOX.
H9c2 cells pre-incubated with either vehicle or 500 μM of NAD+ for 1 hour, then 1 μM of DOX
for 24 hours in culture media. Caspase-3 activity was determined. Data are provided as means ±
SD. A one-way ANOVA analysis followed by the Bonferroni test was performed. A statistical
significance was defined by *p-value ≤ 0.05 and ****p-value ≤ 0.0001.
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3.11 Administration of NMN improves myocardial function in
DOX-injected mice
To investigate the effect of NMN using in vivo methods, I conducted an acute DOX study
in mice. Based on a previous study conducted in our laboratory (54), I used a single dose
of 500 mg/kg for NMN and 20 mg/kg for DOX. NMN was given 30 minutes before a
DOX injection. Five days after DOX injection, the EF and FS percentage were measured
as an indicator of myocardial function by echocardiography (Figure 22).
The mean body weight, heart weight, heart rate, LVIDd, and LVIDs for each group can
be seen in Table 7. No death occurred in the experiment, but we were unable to obtain the
measurements for a mouse in the NMN and saline group. In the DOX injected mice, the
EF was about 45% and FS was 22%, indicative of myocardial dysfunction. Mice pretreated with NMN before DOX injection attenuated myocardial dysfunction as evidenced
by the increase in EF to 70% (Figure 23) and increase to 39% in FS (Figure 24).
Table 7: Echocardiography analysis on adult C57BL/6 male mice injected with
either NMN (500 mg/kg) or saline for 30 minutes, then a DOX (20 mg/kg) or saline
injection.
Treatment Group

N

BW (g)

HW (mg)

HR
(beats/min)

LVIDd
(mm)

LVIDs
(mm)

Vehicle+Saline

5

21.80± 1.94

0.13±0.03

414±69

4.09±0.47

2.34±0.26

NMN+Saline

4

22.77±2.38

0.15±0.04

538±54

4.05±0.51

2.18±0.34

Vehicle+DOX

5

23.31±2.68

0.14±0.04

445±44

4.32±0.60

3.35±0.55

NMN+DOX

5

25.36±1.55

0.12±0.03

470±74

3.95±0.19

2.42±0.19

Data provided as mean ± SD. BW: Body weight, HW: Heart weight, HR: heart rate, LVIDd: left
ventricular internal diameter at diastole, LVIDs: left ventricular internal diameter at systole.
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Figure 22: Representative echocardiography image of adult mice in the acute DOXinduced cardiotoxicity study.
Adult C57BL/6 male mice were injected with either NMN (500 mg/kg) or saline for 30 minutes,
then received a DOX (20 mg/kg) or saline injection. After 5 days, echocardiography was
performed to assess myocardial function.
LVAWd: left ventricular anterior wall at diastole, LVAWs: left ventricular anterior wall at
systole, LVIDd: left ventricular internal diameter at diastole, LVIDs: left ventricular internal
diameter at systole, LVPWd: left ventricular posterior wall at diastole, LVPWs: left ventricular
posterior wall at systole.
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Figure 23: Effect of NMN on ejection fraction in DOX-injected mice.
Adult C57BL/6 male mice were injected with either NMN (500 mg/kg) or saline for 30 minutes,
then received a DOX (20 mg/kg) or saline injection. After 5 days, echocardiography was
performed to assess myocardial function. Data are provided as means ± SD. A one-way ANOVA
analysis followed by the Bonferroni test was performed. A statistical significance was defined by
****p-value ≤ 0.0001.

42

Figure 24: Effect of NMN on fractional shortening in DOX-injected mice.
Adult C57BL/6 male mice were injected with either NMN (500 mg/kg) or saline for 30 minutes,
then a received DOX (20 mg/kg) or saline injection. After 5 days, echocardiography was
performed to assess myocardial function. Data are provided as means ± SD. Data are provided as
means ± SD. A one-way ANOVA analysis followed by the Bonferroni test was performed. A
statistical significance was defined by ****p-value ≤ 0.0001.
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3.12 NMN reduces cardiac injury in DOX injected mice
The Evans blue dye technique allows for the detection of necrotic cell death. To further
assess the in vivo effect of NMN, adult mice were treated with NMN (500 mg/kg, i.p.) for
30 minutes or saline and DOX (20 mg/kg, i.p.). After 5 days, the mice were injected with
Evans blue (100 mg/kg, i.p.). Four hours later the heart was collected, cryosectioned, and
stained with Hoechst 33342 for nuclei (blue colour, Figure 25).

The vehicle saline group did not have any cells stained with Evans blue (red colour,
Figure 23). In the NMN pre-incubation group, there were 0.04% of cells stained with
Evans blue. The vehicle DOX group had a higher percentage of Evans blue staining at
about 1.70% of cells stained. Pre-incubation with NMN decreased cardiac necrosis by
lowering Evans blue staining cells to about 0.04% compared to the vehicle DOX group
(Figure 26).
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Figure 25: Representative micropictures of Evans Blue staining and nuclear
staining.
Evans Blue (100 mg/kg) and Hoechst 33342 (1 mg/mL) staining for cell viability in adult
C57BL/6 mice heart tissues 5 days after injection with either NMN (500 mg/kg) or saline for 30
minutes, then a DOX (20 mg/kg) or saline injection. Images were captured on fluorescence
microscope at 10x and 40x objective. Arrows are pointing to nuclei within the cardiomyocytes.
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Figure 26: Quantification of Evans Blue positive cells in DOX injected mice.
Evans Blue (100 mg/kg) and Hoechst 33342 (1 mg/mL) staining for cell viability in adult
C57BL/6 mice heart tissues 5 days after injection with either NMN (500 mg/kg) or saline for 30
minutes, then a DOX (20 mg/kg) or saline injection. Data are provided as means ± SD. A oneway ANOVA analysis followed by the Bonferroni test was performed. A statistical significance
was defined by **p-value ≤ 0.01.
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3.13 Inhibition of HAT GCN5 with Butyrolactone 3 does not
protect H9c2 cell viability against DOX-induced
cardiotoxicity
To determine the role of HAT GCN5, I treated cells with the Butyrolactone 3 inhibitor. I
seeded 2.0x103 H9c2 cells per well in a 96-well plate. Cells were either pre-incubated
with either vehicle or Butyrolactone 3 for 18 hours, then treated with 1 μM of DOX for
24 hours. I measured the cell viability to help determine cell death using calcein AM. The
results showed that the cell viability in the vehicle DOX decreased by about 20%
compared to control. Pre-treatment with Butyrolactone 3 at 50 and 100 μM did not affect
the cell viability in DOX-treated cells (Figure 27). Therefore, pre-incubating H9c2 cells
with Butyrolactone 3 does not abrogate cell death.

Figure 27: Effect of Butyrolactone 3 on H9c2 cell viability.
H9c2 cells were pre-incubated with either vehicle, 50 μM, or 100 μM of Butyrolactone 3 for 18
hours, then 1 μM of DOX for 24 hours in culture media. Cell viability was measured using 1 μM
of calcein AM. Data are provided as means ± SD. A one-way ANOVA analysis followed by the
Bonferroni test was performed. A statistical significance was defined by ****p-value ≤ 0.0001
and n.s=not significant.
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3.14 Inhibition of HAT TIP60 with MG149 does not block the
effect of DOX treatment on H9c2 cell viability
I treated cells with the MG149 inhibitor to determine the role of HAT TIP60 in the
development of DOX-induced cardiotoxicity. I seeded 2.0x103 H9c2 cells per well into a
96-well plate and either pre-incubated cells with DMSO or the inhibitor for 18 hours,
then treated cells with 1 μM of DOX for 24 hours. The results reveal that the percentage
of cell viability in the DOX treated and MG149 pre-incubated group were both about
78% (Figure 28). H9c2 cells pre-incubated with MG149 did not block the effect of DOX.

Figure 28: Effect of MG149 on H9c2 cell viability.
H9c2 cells pre-incubated with either vehicle or 10 μM of MG149 for 18 hours, then 1 μM of
DOX for 24 hours in culture media. Cell viability was measured using 1 μM of calcein AM. Data
are provided as means ± SD. A one-way ANOVA analysis followed by the Bonferroni test was
performed. A statistical significance was defined by ***p-value ≤ 0.001 and n.s=not significant.
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3.15 Inhibition of HAT p300/CBP with C646 does not block
DOX’s effect on H9c2 cell viability
I determined the role of HAT p300/CBP using the C646 inhibitor. Similar to the previous
cell viability experiments, I use the calcein AM assay to determine cell viablilty after
treatment with DOX. I seeded 2.0x103 cells per well into a 96-well plate and either preincubated cells with either DMSO, 2 μM, 10 μM, or 30 μM of C646 for 18 hours, then 1
μM of DOX for 24 hours in culture media. The results show that the vehicle control
group had a 35% decrease in cell viability, indicating lower cell viability than the control.
The group pre-treated with 2 μM and 10 μM of C646 had a slight 4% increase in cell
viability compared to the vehicle DOX group. Also, the group treated with 30 μM of
C646 has the same cell viability percentage as the vehicle DOX treated group (Figure
29). This suggests that C646, an inhibitor of p300 may not be able to prevent DOXinduced cardiotoxicity.

Figure 29: Effect of C646 on H9c2 cell viability.
H9c2 cells pre-incubated with either vehicle, 2 μM, 10 μM, or 30 μM of C646 for 18 hours, then
1 μM of DOX for 24 hours in culture media. Cell viability was measured using 1 μM of calcein
AM. Data are provided as means ± SD. A one-way ANOVA analysis followed by the Bonferroni
test was performed. A statistical significance was defined by ****p-value ≤ 0.0001 and n.s=not
significant.
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3.16 Inhibition of HAT p300 with HAT inhibitor II does not
block DOX effect on H9c2 cell viability
To identify the role of HAT p300, I used the HAT inhibitor II. I used calcein AM to
determine the effect of HAT inhibitor II on H9c2 cell viability. I seeded 2.0x103 cells per
well into a 96-well plate and either pre-incubated cells with either DMSO or the inhibitor
for 18 hours, then 1 μM of DOX for 24 hours. The findings show that there was no
difference in H9c2 cell viability when cells were treated with HAT inhibitor II at 5 μM or
10 μM. The vehicle DOX group had a 30% decrease in cell viability compared to the
control. The pre-incubated HAT inhibitor II group at 5 μM had an increase in cell
viability by 3% compared to the vehicle DOX group. Also, the pre-incubated HAT
inhibitor II group at 10 μM had the same cell viability compared to the vehicle DOX
group (Figure 30).

Figure 30: Effect of HAT inhibitor II on H9c2 cell viability.
H9c2 cells pre-incubated with either DMSO, 5 μM, or 10 μM of HAT inhibitor II for 18 hours,
then 1 μM of DOX for 24 hours in culture media. Cell viability was measured using 1 μM of
calcein AM. Data are provided as means ± SD. A one-way ANOVA analysis followed by the
Bonferroni test was performed. A statistical significance was defined by ****p-value ≤ 0.0001
and n.s=not significant.
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Chapter 4

4

Discussion, Limitations, and Future Directions

4.1 Discussion
4.1.1

DOX induces damage in a dose-dependent manner

DOX induced damage in H9c2 cells in a dose-dependent as revealed by the LDH release
(Figure 12), caspase-3 activity (Figure 13), and calcein AM (Figure 14) experiments from
0, 1, 2, and 5 μM of DOX. Our findings are consistent with previously published papers
showing DOX induces damage in a dose-dependent manner in vitro (86–88). Apoptotic
cell death in H9c2 cells was observed to be time and dose-dependent confirming the
caspase-3 activity findings in this study (99). Necrosis cell death measured by LDH
release shows dose-dependent damage at 24 hours (100).
Further increasing DOX dose above 5 μM decreased H9c2 cell viability in a dosedependent response manner (101). Thus, we chose to limit our study to 5 μM of DOX. To
address why the concentration at 50% of cell viability loss varies across the different
studies, it may be a difference in passage number that affects increases cellular sensitivity
to stress conditions (102). There is a consistent trend from previous studies and this study
that DOX elicits damage in a dose-dependent manner.

4.1.2

Increasing NAD+ concentration prevents DOX damage in
H9c2 cells

DOX reduces NAD+ concentration (Figure 15) and pre-treating with NMN does promote
NAD+ in H9c2 cells (Figure 16). Pre-treating H9c2 cells with NMN before DOX
treatment reduced LDH release (Figure 17) and lower caspase-3 activity (Figure 18).
Also, cell viability increased with pre-treatment of NMN compared to the DOX only
group (Figure 19). We have shown that NMN can attenuate DOX-induced cardiotoxicity
by increasing NAD+ concentration in H9c2 cells. Our study reveals novel in vitro
findings that NMN protects against DOX-induced cardiotoxicity through increasing
NAD+ concentration to prevent cell death. Furthermore, pre-incubating H9c2 cells with
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NAD+ free acid for 1 hour resulted in higher cell viability (Figure 20) and decreased
caspase-3 activity (Figure 21). This finding is consistent with previous research that
exogenous NAD+ increased intracellular NAD+ concentration in H9c2 cells (103).
The downstream molecular mechanisms following NAD+ was not examined in this study.
Previous research shows that EX-527 attenuated the protective effect of NR, which
suggests that NR acts through the NAD+/SIRT1 pathway (54). We predict that NMN
could function through the same pathway to provide protection. SIRT1 is involved in
inducing autophagy to protect cardiomyocytes from stressors (104). SIRT1 may directly
facilitate autophagic flux by preventing acetylation on Vacuolar ATPase and maintaining
the acidic lysosomal environment to allow for degradation of accumulated cargo (30).
Further investigation into the molecular mechanisms including the relationship between
SIRT1 and Vacuolar ATPase would be important to understanding DOX-induced
cardiotoxicity’s mechanism.

4.1.3

NMN protects mice hearts against DOX

EF% is the percentage of volumetric blood that is being pumped out of the heart per
cardiac cycle. A decline in EF% indicates that the heart is not effectively pumping as
much blood volume out, thus there is blood remaining in the ventricle. FS% is the
percentage of change in the diameter of the ventricle after a cardiac cycle. Similarly, a
decrease in FS% suggests a decrease in cardiac function. We found that 5 days after a
DOX injection, mice pre-treated with NMN had higher EF% (Figure 23) and FS%
(Figure 24) compared to the vehicle treated group, which indicates improved myocardial
function.

We can confirm that the Evans Blue dye stained for cardiomyocytes as the cell has an
elongated rod shape and contains multiple nuclei (Figure 25) (105,106). Evans Blue
staining showed that mice injected with NMN before DOX had fewer positive cells
stained compared to DOX only group (Figure 26). This indicates that there is reduced
cardiac injury. It has been shown that DOX induced necrosis on cardiomyocytes and NR
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was able to inhibit DOX’s effect using the Evans Blue technique (54). No published
studies have examined NMN’s effect on DOX treated mice using Evans Blue staining.

The results from this study are consistent with a published article that shows NMN
converts into NAD+ to preserve cardiac function (58). NMN supplementation prevented
cardiomyopathy by increasing heart tissue NAD+ concentration in DOX treated mice
(58), similar to our in vitro results (Figure 14). Our in vivo finding is the first to show that
NMN can protect mouse hearts from an acute DOX-induced cardiotoxicity study. We
have provided novel data from the Evans Blue data to further support NMN protective
effects. Therefore, boosting NAD+ with NMN protects against DOX-induced
cardiotoxicity in the H9c2 cell line and attenuates myocardial dysfunction in DOXinjected adult mice.
While NR has previously shown cardioprotective effects, NMN contains several potential
advantages over NR. A newly discovered NMN transporter has shown that NMN can
directly enter the cell (52). Direct entry into the cell makes NMN conversion into NAD+
more effective since it does not dependent on the rate-limiting activity of NRK1/2.
Furthermore, NR is more unstable and degrades into NAM in murine plasma compared to
NMN (50). NMN can be rapidly absorbed into the blood circulation from the gut within 3
minutes, then into tissues within 15 minutes (107,108). Therefore, NMN has several
advantages over NR and is a promising compound for future research.

4.1.4

Selective HAT inhibitors have no effect on H9c2 cells treated
with DOX

We selected the HAT inhibitors in this study based on 3 criteria including specificity,
availability, and cost of HAT inhibitors. The first criterion is the specificity of the HAT
inhibitor. We choose HAT inhibitors that would inhibit specific HAT family members
since we would be able to eliminate or attribute the effect to a specific member. The
second criterion is the availability of the HAT inhibitors, where we selected HAT
inhibitors that were readily available from a pharmaceutical company. Lastly, the final
criterion is the cost of the HAT inhibitors, and this criterion helps to ensure that the
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project was feasible. Based on these criteria, we selected Butyrolactone 3, MG149, C646,
and HAT inhibitor II.
In this study, we found there was no effect on H9c2 cell viability when treated with the
various HAT inhibitors. Butyrolactone 3 inhibits HAT GNC5 and there was no effect on
H9c2 cells when pre-treated with the inhibitor for 18 hours before DOX treatment
(Figure 27). Currently, no studies have examined the effect of Butyrolactone 3 in DOXinduced cardiotoxicity. Our finding provides novel insight into the effect of
Butyrolactone 3 on H9c2 cell viability treated with DOX.
Similarly, when H9c2 cells were treated with MG149, which inhibits HAT TIP60, we
showed that MG149 at 10 μM did not affect cell viability (Figure 28). A recently
published article revealed that hyperacetylation of GATA4, a member of the GATA
transcription factor family protected against DOX (109). While the hypoacetylation
caused by administering MG149 at 20 μM resulted in a loss of its protective effect (109).
DOX treatment impairs the SIRT6-TIP60-GATA4 trimeric complex which blocks
GATA4 acetylation leading to cardiomyocyte apoptosis (109). These findings contradict
our proposed model, as the regulation between SIRT6 and TIP60 function together to
prevent DOX-induced cardiotoxicity. One potential reason as to why our results are
inconsistent with the published article maybe because we used a lower dosage.
Nevertheless, our finding provides information into the effect of MG149 on H9c2 cells
treated with DOX.

There was no effect on H9c2 cell viability when pre-treated with HAT p300/CBP
inhibitor C646 at 2, 10, and 30 μM compared to DOX treatment alone (Figure 29). A
study that revealed inhibition of p53 acetylation with C646 prevented DOX-induced
cardiotoxicity in normal bone marrow cells with maintaining DOX’s anti-cancer efficacy
(74). C646 prevented DOX-induced toxicity by inhibiting p53 activity, a substrate to
p300 (74). We have provided new evidence to show that C646 has no effect on H9c2 cell
viability treated with DOX.
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We found that pre-treating H9c2 cells with HAT inhibitor II at 5 and 10 μM, which
inhibits p300 did not have an effect (Figure 30). To date, there are no studies examining
HAT inhibitor II in the development of DOX-induced cardiotoxicity. Therefore, our
finding provides novel insight into the effect of HAT inhibitor II on cells treated with
DOX.

In summary, pre-treatment of HAT inhibitors has no effect on H9c2 cell viability treated
with DOX. We have showcased new insights into the effects of various HAT inhibitors
on H9c2 cell viability treated with DOX. Based on our findings, it suggests that HATs
GCN5, TIP60, and p300/CBP does not play a role in DOX-induced cardiotoxicity.
Further studies to determine whether other HAT family members are involved is required
to fully understand the role of HAT in DOX-induced cardiotoxicity.

4.2 Limitations
There are several limitations to the NMN research study that requires further
investigation. We conducted an acute DOX-induced cardiotoxicity model with a single
DOX injection for 5 days. The findings from our acute DOX-induced cardiotoxicity
study may not be clinically relevant or be generalized to chronic DOX-induced
cardiotoxicity, it does provide useful insights potential therapeutics for DOX-induced
cardiotoxicity. Also, the research project does not examine the effect of NMN on DOX’s
anti-cancer effect. The focus of our research project was to determine and understand
NMN’s protective properties against DOX. We did not examine whether pre-treating
cells with NMN affected DOX’s ability to stop cancer cell proliferation. However, it has
been shown that NAD+ prevents cancer cell metabolism and provides an anti-tumor effect
in cancers (110,111).

There are several limitations to the HAT study as well. First, the selected HAT inhibitors
that were used in this study did not protect against DOX in H9c2 cells. There are multiple
different HAT inhibitors and the chosen inhibitors in this study including HAT inhibitor
II, MG149, Butyrolactone 3, and C646, were based on availability on the market, cost,
and selective inhibition on HAT family member. One reason why the HAT inhibitor
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shows no effect may be because the inhibitor functions to inhibit a specific HAT family
member, while other HAT members may be able to compensate for the loss of activity.
For example, Butyrolactone 3 inhibits GCN5 activity, however with the reduced activity
of GCN5, perhaps PCAF increases its activity to compensate for the loss (112).
Therefore, the global activity of HAT remains the same and results in DOX-induced
cardiotoxicity.

4.3 Future Directions
To address the NMN limitations, a future direction is to conduct a study to determine if
the protective effects of NMN are consistent in a chronic model of DOX-induced
cardiotoxicity in adult mice as well, a more clinically relevant model. Being able to
replicate the findings in a chronic mice model would further confirm NMN protective
effects against DOX in an acute and chronic mice model. Another future direction would
be to examine whether NMN impacts DOX’s anti-cancer activity. DOX’s functions
through a multiple mechanism of action and whether NMN interferes remains to be
determined. NR was found to prevent tumour formation (113), so NMN could have a
similar effect on tumours growth which would further support its merits for clinical use.

Other HAT inhibitors could be effective in preventing DOX-induced cardiotoxicity.
Another future direction would be to use a Pan-HAT inhibitor, which will inhibit the
activity of multiple HAT family members. This will help to further help understand the
role of HAT in the development of DOX-induced cardiotoxicity by inhibiting various
HAT family members at once. There is a pan-HAT inhibitor called PU139, which blocks
GCN5, PCAF, CBP, and p300 (114). Researchers found that when PU139 was combined
with DOX, there was a synergistic effect on blocking the growth of neuroblastoma cells
(114). With limited research on the effect of PU139, it is difficult to determine the effect
on non-cancerous cells. We predict that a pan-HAT inhibitor can lower acetylation levels
in cardiomyocytes to protect against DOX.
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4.4 Project Significance
Intense efforts should be taken to establish preventive options against DOX-induced
cardiotoxicity as the number of cancer patients will rise. Our research contributes to
discovering potential preventive therapeutic options for patients suffering from DOXinduced cardiotoxicity. NMN may be a potential preventive option for patients
experiencing DOX-induced cardiotoxicity. Thus, this study lays an important foundation
for future clinical trials using NMN to prevent DOX-induced cardiotoxicity in patients
receiving anthracycline chemotherapy.
Furthermore, the results from the HAT inhibitor study suggest that specific HAT family
members may not be involved in DOX-induced cardiotoxicity. With limited studies
examining HAT in DOX-induced cardiotoxicity, this study contributes to advancing
scientific literature and identifying the potential roles of HATs.

4.5 Concluding Remarks
The main findings in this study reveal that pre-treatment of NMN prevented DOX
damage by increasing NAD+ concentration and that NMN is an effective approach to
reduce DOX-induced cardiotoxicity. Although the molecular mechanism is not fully
elucidated, this study shows that NAD+ plays an important role in preventing DOX’s
damage. Since NMN is a health supplement, our findings can be conveniently translated
into clinical patients in the future.

HAT inhibitors Butyrolactone 3, MG149, C646, and HAT inhibitor II has no effect on
H9c2 cells treated with DOX. Further research into HATs and HDACs are required to
understand its’ effect in the development of DOX-induced cardiotoxicity.
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